Cugno M, Salerno F, Nussberger J, Bottasso B, Lorenzano E, Agostoni A
Department of Internal Medicine, University of Milan, Maggiore Hospital IRCCS, Via Pace 15, 20122 Milan, Italy.
Clin Sci (Lond). 2001 Dec;101(6):651-7.
Bradykinin, a nonapeptide with vasodilatory and permeabilizing activity, is generated through the cleavage of high-M(r) ('high-molecular-weight') kininogen by kallikrein, and its generation is facilitated by plasmin. In the ascitic fluid of patients with cirrhosis, there is massive cleavage of high-M(r) kininogen and activation of fibrinolysis, but bradykinin has never been measured directly. In the ascitic fluid of 24 patients with cirrhosis, we measured bradykinin-(1-9)-nonapeptide levels by RIA after liquid-phase and subsequent HPLC extraction, and those of its catabolic product bradykininin-(1-5)-pentapeptide by ELISA after liquid-phase extraction. Cleaved high-M(r) kininogen, activated factor XII and plasmin-antiplasmin complexes were measured in ascitic fluid and plasma. Plasma renin activity (PRA) was also determined. As a control, we also analysed plasma from 24 healthy subjects matched for sex and age with the patients. In the ascitic fluid from patients with cirrhosis, the median bradykinin-(1-9) concentration was 3.3 fmol/ml (range 0.2-29.0 fmol/ml), and the median bradykinin-(1-5) concentration was 210 fmol/ml (range 58-7825 fmol/ml). The levels of bradykinin-(1-5) in ascitic fluid were higher in patients with refractory ascites [median 1091 fmol/ml (range 58-7825 fmol/ml)] than in patients with responsive ascites [134 fmol/ml (72-1084 fmol/ml)] (P=0.010). Ascitic fluid levels of bradykinin-(1-9) were not related to the severity of ascites. PRA was higher in patients with refractory ascites [23.0 ng x h(-1) x ml(-1) (7.9-80.0 ng.h(-1).ml(-1))] than in patients with responsive ascites [6.9 ng x h(-1) x ml(-1) (0.9-29.4 ng x h(-1) x ml(-1))] (P=0.002). In ascitic fluid, 48% (19-68%) of high-M(r) kininogen was cleaved, and plasmin-antiplasmin complexes were more concentrated than in plasma (P=0.0001). In conclusion, in the ascitic fluid of patients with cirrhosis, both bradykinin-(1-9) and bradykinin-(1-5) are present, with cleavage of high-M(r) kininogen and activation of fibrinolysis. The highest levels of the long-lived metabolite bradykinin-(1-5) were found in the ascitic fluid of patients with refractory ascites and high PRA. Activation of the kinin system may therefore be involved in decompensating cirrhosis, but a cause-effect relationship remains to be established.
缓激肽是一种具有血管舒张和通透活性的九肽,通过激肽释放酶裂解高分子量激肽原而产生,纤溶酶可促进其生成。在肝硬化患者的腹水中,高分子量激肽原大量裂解,纤溶系统激活,但缓激肽从未被直接检测过。我们采用放射免疫分析(RIA)法,在液相及随后的高效液相色谱(HPLC)提取后,检测了24例肝硬化患者腹水中缓激肽-(1-9)九肽的水平;采用酶联免疫吸附测定(ELISA)法,在液相提取后,检测了其分解产物缓激肽-(1-5)五肽的水平。同时检测了腹水中及血浆中裂解的高分子量激肽原、活化的因子Ⅻ和纤溶酶-抗纤溶酶复合物。还测定了血浆肾素活性(PRA)。作为对照,我们分析了24名年龄和性别与患者匹配的健康受试者的血浆。肝硬化患者腹水中缓激肽-(1-9)的中位浓度为3.3 fmol/ml(范围0.2 - 29.0 fmol/ml),缓激肽-(1-5)的中位浓度为210 fmol/ml(范围58 - 7825 fmol/ml)。难治性腹水患者腹水中缓激肽-(1-5)的水平[中位值1091 fmol/ml(范围58 - 7825 fmol/ml)]高于反应性腹水患者[134 fmol/ml(72 - 1084 fmol/ml)](P = 0.010)。腹水中缓激肽-(1-9)的水平与腹水严重程度无关。难治性腹水患者的PRA[23.0 ng·h⁻¹·ml⁻¹(7.9 - 80.0 ng·h⁻¹·ml⁻¹)]高于反应性腹水患者[6.9 ng·h⁻¹·ml⁻¹(0.9 - 29.4 ng·h⁻¹·ml⁻¹)](P = 0.002)。腹水中48%(19% - 68%)的高分子量激肽原被裂解,且纤溶酶-抗纤溶酶复合物比血浆中更浓缩(P = 0.0001)。总之,在肝硬化患者的腹水中,缓激肽-(1-9)和缓激肽-(1-5)均存在,伴有高分子量激肽原的裂解和纤溶系统的激活。在难治性腹水和高PRA患者的腹水中发现了寿命较长的代谢产物缓激肽-(1-5)的最高水平。因此,激肽系统的激活可能参与了肝硬化失代偿,但因果关系仍有待确立。